<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537847</url>
  </required_header>
  <id_info>
    <org_study_id>Sitafloxacin123</org_study_id>
    <nct_id>NCT02537847</nct_id>
  </id_info>
  <brief_title>Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli</brief_title>
  <acronym>SETAP</acronym>
  <official_title>A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigators' study was to evaluate oral and non carbapenem antimicrobial
      agents which can be used in outpatient for the treatment of non-bacteremic acute
      pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia coli. This study was
      conducted to compare the clinical and bacteriological outcomes of patients with
      non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia
      coli who were treated with intravenous (IV) carbapenems followed by oral sitafloxacin or IV
      ertapenem.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized controlled trial of patients with a presumptive diagnosis of acute
      pyelonephritis caused by Extended Spectrum Beta Lactamase-producing pathogen was performed.
      Carbapenems was initially given to all patients. After day 3, patients were randomized to
      receive either oral sitafloxacin (100 mg twice daily) or intravenous ertapenem. The regular
      course of treatment was completed within 10 days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>no symptoms of urinary tract infection</measure>
    <time_frame>30 days</time_frame>
    <description>no fever, dysuria, back pain, nausea and vomiting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>no evidence of Extended Spectrum Beta Lactamase Escherichia coli in urine culture</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Infection Due to Escherichia Coli</condition>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Sitafloxacin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention was prescribed ertapenem for patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitafloxacin</intervention_name>
    <description>The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.</description>
    <arm_group_label>Sitafloxacin group</arm_group_label>
    <other_name>fluoroquinolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Control group will be given ertapenem only for 10 days.</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>carbapenem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Acute pyelonephritis by definition

          -  Positive urine culture for Extended Spectrum Beta Lactamase Escherichia coli ≥105
             colony forming unit/mL

          -  Voluntarily consented to be enrolled in the study

        Exclusion Criteria:

          -  Severe sepsis or septic shock

          -  Mixed organism of urine culture

          -  Positive blood culture

          -  Has other source of infection

          -  Has mechanical abnormality of urinary tract

          -  Immunocompromised conditions

          -  Retained Foley's catheter

          -  Pregnancy or lactation

          -  Previous urinary tract infections within 4 weeks

          -  Contraindicated for fluoroquinolones and carbapenems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sasisopin Kiertiburanakul</last_name>
    <role>Study Director</role>
    <affiliation>Ramathibodi Hospital Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chitprasong Malaisri, MD</last_name>
    <phone>+66 89 466 5043</phone>
    <email>Mchitprasong@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chitprasong Malaisri, MD</last_name>
      <phone>++66 89 466 5043</phone>
      <email>Mchitprasong@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>August 28, 2015</last_update_submitted>
  <last_update_submitted_qc>August 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Chitprasong Malaisri</investigator_full_name>
    <investigator_title>Ramathibodi Hospital</investigator_title>
  </responsible_party>
  <keyword>Sitafloxacin</keyword>
  <keyword>Extended-Spectrum ß-lactamase-producing Escherichia coli</keyword>
  <keyword>Treatment for Acute Pyelonephritis</keyword>
  <keyword>Ertapenem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyelonephritis</mesh_term>
    <mesh_term>Escherichia coli Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Sitafloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

